Taofeek Kunle Owonikoko, MD, PhD, on Small Cell Lung Cancer: Tremelimumab and Durvalumab With or Without Radiation
2019 ASCO Annual MeetingTaofeek Kunle Owonikoko, MD, PhD, of Emory University, discusses the findings of his phase II study, which assessed the efficacy of combined immune checkpoint inhibitors with or without radiation in relapsed small cell lung cancer (Abstract 8515).
Related Videos
Neeraj Agarwal, MD, and Arnaud Méjean, MD, PhD, on Renal Cancer: Cytoreductive Nephrectomy Followed by Sunitinib in the Metastatic Setting
Neeraj Agarwal, MD, of the Huntsman Cancer Institute, and Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges-Pompidou, Paris Descartes University, discu...
Ahmad A. Tarhini, MD, PhD, on High-Risk Melanoma: Adjuvant Ipilimumab vs High-Dose Interferon-α2b
Ahmad A. Tarhini, MD, PhD, of Emory University and Winship Cancer Institute, discusses phase III findings from the U.S. Intergroup E1609 trial, which showed survival benefits for p...
Hirotsugu Kenmotsu, MD, on Nonsquamous Non–Small Cell Lung Cancer: Pemetrexed Plus Cisplatin vs Vinorelbine Plus Cisplatin
Hirotsugu Kenmotsu, MD, of Shizuoka Cancer Center, discusses the phase III JIPANG trial findings, which showed that pemetrexed plus cisplatin was not superior to vinorelbine plus c...
Miriam Knoll, MD, and Richard J. White, DO, on Non–Small Cell Lung Cancer: Predicting Radiotherapy/Immunotherapy Treatment Outcomes
Miriam Knoll, MD, of Hackensack University Medical Center, and Richard J. White, DO, of Allegheny Health Network, discuss improved overall survival among you...
Margaret A. Tempero, MD, on Pancreatic Cancer: Adjuvant Nab-paclitaxel and Gemcitabine
Margaret A. Tempero, MD, discusses phase III results from the multicenter APACT trial, which showed that adjuvant nab-paclitaxel plus gemcitabine may be an option for patients who ...
